Tracon completes enrollment in Ph IIb TRAXAR trial of TRC105 to treat RCC

Tracon Pharmaceuticals Inc. (NASDAQ:TCON) completed enrollment of 150 patients with advanced or metastatic renal cell carcinoma (RCC) who failed 1 prior VEGF inhibitor in the Phase IIb TRAXAR trial comparing carotuximab (TRC105) plus Inlyta axitinib to Inlyta alone. The open-label, international trial's primary endpoint is progression-free survival (PFS). The company expects top-line data from the trial this year.

Secondary endpoints include overall response rate (ORR), disease control rate (DCR), time to first metastasis, safety and immunogenicity...